Researcher

My Expertise

I am a nationally and internationally recognised leader in research leveraging linked administrative health data to investigate cancer treatment, outcomes, and national cancer policies. I have a strong focus on HER2-positive breast cancer, biologic cancer therapies, and the policies governing access to these treatments. I apply population health science methods to inform clinical, policy, and patient decisions. I promote policy that supports the quality use of medicines and good practice in the access to and use of real-world data for research purposes.

Keywords

Fields of Research (FoR)

Cancer and related disorders, Epidemiology, Public Health and Health Services

SEO tags

Biography

I am a pharmacoepidemiologist specialising the analysis of linked administrative health data to understand the use and outcomes of medicines, with a particular focus on cancer treatments and cancer pharmacoepidemiology. I have over 10 years' experience as a biostatistician and analyst, leading statistical analyses for multi-disciplinary research teams spanning laboratory-based, epidemiology, and public health research at UNSW and the...view more

I am a pharmacoepidemiologist specialising the analysis of linked administrative health data to understand the use and outcomes of medicines, with a particular focus on cancer treatments and cancer pharmacoepidemiology. I have over 10 years' experience as a biostatistician and analyst, leading statistical analyses for multi-disciplinary research teams spanning laboratory-based, epidemiology, and public health research at UNSW and the University of Sydney. I am currently a Senior Research Fellow within the Medicines Intelligence Group at the School of Population Health, UNSW Sydney. My current and past projects include: a comprehensive examination of the treatment and outcomes in women treated with trastuzumab for metastatic breast cancer through the Herceptin Program in Australia (2001 - 2015) and ongoing research into the use and outcomes associated with HER2-targeted therapies; the impact of COVID-19 policies on cancer care; risks of developing cancers associated with medications to treat chronic conditions; multiple medicine use (polypharmacy); the use of opioids in cancer treatment; and evaluating the impact of national medicines policies.


My Grants

  • Cancer Institute NSW Early Career Fellowship (2022 - 2025; $345,000), "Leveraging big data for real-world evidence generation: Impact of multi-medicine use on bowel cancer treatment and survivorship outcomes" 
  • UNSW Cancer Seed Grant (2022; $50,000), "Understanding the impact of SARS-CoV-2 (COVID-19) on Australian cancer treatment"
  • NHMRC Ideas Grant, "Disentangling the interrelationship between multimordibity, multimedicine use, and cardiovascular health" (Associate Investigator) (2021 - 2023; $480,000)
  • NHMRC Post-graduate scholarship (2015-2018; $84,000) 

My Qualifications

  • PhD, Pharmacoepidemiology (University of New South Wales)
  • MA, Sociology & Statistics (McGill University)
  • BSc, Psychology (Drexel University)

My Awards

  • 2020 - UNSW Medicine Early Career Academic Network (ECAN) Best Paper Award - Public Health 

My Research Supervision


Supervision keywords


Areas of supervision

I am available to supervisie ILP and honours year students and to co-supervise postgraduate students.


Currently supervising

Jun Ni Ho (PhD candidate) - 'Optimisation of Risk Management for Biologic Medicines in Australia'

 

View less